Last reviewed · How we verify
Low-dose heparin
Low-dose heparin is a Anticoagulant Small molecule drug developed by San Filippo Neri General Hospital. It is currently FDA-approved for Venous thromboembolism prophylaxis in hospitalized patients, Prevention of deep vein thrombosis in surgical patients, Thromboprophylaxis in medical patients with reduced mobility. Also known as: 50 UI/Kg bolus heparin.
Low-dose heparin inhibits blood coagulation by potentiating antithrombin III, which inactivates clotting factors IIa and Xa.
Low-dose heparin inhibits blood coagulation by potentiating antithrombin III, which inactivates clotting factors IIa and Xa. Used for Venous thromboembolism prophylaxis in hospitalized patients, Thromboprophylaxis in surgical patients, Prevention of deep vein thrombosis and pulmonary embolism.
At a glance
| Generic name | Low-dose heparin |
|---|---|
| Also known as | 50 UI/Kg bolus heparin |
| Sponsor | San Filippo Neri General Hospital |
| Drug class | Anticoagulant |
| Target | Antithrombin III (indirect target); Thrombin (Factor IIa) and Factor Xa (downstream targets) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Heparin is an anticoagulant that works by binding to and enhancing the activity of antithrombin III, a natural inhibitor of blood coagulation. This complex inactivates thrombin (factor IIa) and factor Xa, preventing the formation of fibrin clots. Low-dose heparin is used primarily for thromboprophylaxis rather than treatment of established thrombosis.
Approved indications
- Venous thromboembolism prophylaxis in hospitalized patients
- Prevention of deep vein thrombosis in surgical patients
- Thromboprophylaxis in medical patients with reduced mobility
Common side effects
- Bleeding
- Heparin-induced thrombocytopenia (HIT)
- Injection site reactions
- Osteoporosis (with prolonged use)
Key clinical trials
- Effect of Anticoagulant Therapy on Endometrial Receptivity and Pregnancy Outcomes in Infertility
- Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
- Timing of Venous Thromboembolism Prophylaxis in Patients With Hypertensive Intracerebral Hemorrhage (NA)
- The Intensive Care Platform Trial (PHASE4)
- Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis (PHASE3)
- Utilizing Anti-Factor Xa as a Predictive Tool for Optimizing Outcome in Burn Patients' Management (NA)
- Safe and Fast Radial Hemostasis Using Synergistic Strategies: SAFE & FAST Trial (NA)
- A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low-dose heparin CI brief — competitive landscape report
- Low-dose heparin updates RSS · CI watch RSS
- San Filippo Neri General Hospital portfolio CI
Frequently asked questions about Low-dose heparin
What is Low-dose heparin?
How does Low-dose heparin work?
What is Low-dose heparin used for?
Who makes Low-dose heparin?
Is Low-dose heparin also known as anything else?
What drug class is Low-dose heparin in?
What development phase is Low-dose heparin in?
What are the side effects of Low-dose heparin?
What does Low-dose heparin target?
Related
- Drug class: All Anticoagulant drugs
- Target: All drugs targeting Antithrombin III (indirect target); Thrombin (Factor IIa) and Factor Xa (downstream targets)
- Manufacturer: San Filippo Neri General Hospital — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Venous thromboembolism prophylaxis in hospitalized patients
- Indication: Drugs for Prevention of deep vein thrombosis in surgical patients
- Indication: Drugs for Thromboprophylaxis in medical patients with reduced mobility
- Also known as: 50 UI/Kg bolus heparin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing